

**DEPARTAMENT DE BIOLOGIA CEL·LULAR I ANATOMIA PATOLÒGICA
FACULTAT DE MEDICINA
UNIVERSITAT DE BARCELONA**

**PROGRAMA DE DOCTORAT
BIOLOGIA I PATOLOGIA CEL·LULARS
Bienni 2002-2004**



**ANÀLISI DELS MECANISMES MOLECULARS IMPLICATS EN
EL DESENVOLUPAMENT I PROGRESSIÓ
DELS LIMFOMES DE CÈL·LULA B PETITA**

**Tesi presentada per Verònica Fernández Pascual
per optar al grau de Doctora en Biologia**

**Director de tesi: Dr. Elías Campo Güerri
Tutor: Dr. Carles Enrich Bastús
Barcelona 2008**

Un llegeix per fer-se preguntes (*Franz Kafka*)

BIBLIOGRAFIA

- 1 Muñoz A. Cáncer: genes y nuevas terapias. Editorial Hélice, 1997.
- 2 Evans LS, Hancock BW. Non-Hodgkin lymphoma. *Lancet* 2003; 362:139-146.
- 3 Gómez-Codina J. Linfomas B y T. Biología, clínica y tratamiento. Roche-Aula Médica, 2002.
- 4 Chan JK. The new World Health Organization classification of lymphomas: the past, the present and the future. *Hematol Oncol* 2001; 19:129-150.
- 5 Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994; 84:1361-1392.
- 6 Jox A, Wolf J, Diehl V. Hodgkin's disease biology: recent advances. *Hematol Oncol* 1997; 15:165-171.
- 7 Kuppers R, Hansmann ML. The Hodgkin and Reed/Sternberg cell. *Int J Biochem Cell Biol* 2005; 37:511-517.
- 8 Nakatsuka S, Aozasa K. Epidemiology and pathologic features of Hodgkin lymphoma. *Int J Hematol* 2006; 83:391-397.
- 9 Nishikori M, Uchiyama T. Molecular pathogenesis of Hodgkin lymphoma. *Int J Hematol* 2006; 83:398-403.
- 10 Gamberi B, Gaidano G, Parsa N, Carbone A, Roncella S, Knowles DM et al. Microsatellite instability is rare in B-cell non-Hodgkin's lymphomas. *Blood* 1997; 89:975-979.
- 11 Macintyre E, Willerford D, Morris SW. Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma. *Hematology (Am Soc Hematol Educ Program)* 2000;180-204.
- 12 Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma--a review. *Acta Oncol* 2006; 45:258-271.
- 13 Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. *Oncogene* 2004; 23:6524-6534.
- 14 Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. *Blood* 2004; 103:4389-4395.
- 15 Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. *J Clin Invest* 2005; 115:755-764.
- 16 Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B, Richards SJ et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. *Blood* 2002; 100:2289-2290.
- 17 Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. *Blood* 2004; 104:1850-1854.

- 18 Herishanu Y, Polliack A. Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors influencing prognosis and therapeutic options. *Transfus Apher Sci* 2005; 32:85-97.
- 19 Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukaemia. *Blood* 2006; 108:638-644.
- 20 Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. *N Engl J Med* 2005; 352:804-815.
- 21 Kokhaei P, Palma M, Mellstedt H, Choudhury A. Biology and treatment of chronic lymphocytic leukemia. *Ann Oncol* 2005; 16 Suppl 2:ii113-ii123.
- 22 Dunphy CH. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. *Arch Pathol Lab Med* 2006; 130:483-520.
- 23 Dyer MJ, Oscier DG. The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia. *Leukemia* 2002; 16:973-984.
- 24 Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. *Blood* 1999; 94:1840-1847.
- 25 Capello D, Guarini A, Berra E, Mauro FR, Rossi D, Ghia E et al. Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. *Leukemia* 2004; 18:1941-1947.
- 26 Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood* 1999; 94:1848-1854.
- 27 Mauerer K, Zahrieh D, Gorgun G, Li A, Zhou J, Ansen S et al. Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. *Br J Haematol* 2005; 129:499-510.
- 28 Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. *Blood* 2004; 104:2879-2885.
- 29 Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000; 343:1910-1916.
- 30 Sindelarova L, Michalova K, Zemanova Z, Ransdorfova S, Brezinova J, Pekova S et al. Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia. *Cancer Genet Cytogenet* 2005; 160:27-34.
- 31 Stilgenbauer S, Lichter P, Dohner H. Genetic features of B-cell chronic lymphocytic leukemia. *Rev Clin Exp Hematol* 2000; 4:48-72.

- 32 Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. *N Engl J Med* 2003; 348:1764-1775.
- 33 Absi A, Hsi E, Kalaycio M. Prolymphocytic leukemia. *Curr Treat Options Oncol* 2005; 6:197-208.
- 34 Bea S, Lopez-Guillermo A, Ribas M, Puig X, Pinyol M, Carrio A et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). *Am J Pathol* 2002; 161:957-968.
- 35 Cobo F, Martinez A, Pinyol M, Hernandez L, Gomez M, Bea S et al. Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. *Leukemia* 2002; 16:1028-1034.
- 36 Robak T. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. *Hematology* 2004; 9:387-400.
- 37 Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. *Hematol Oncol* 2006; 24:22-27.
- 38 Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. *Semin Hematol* 1999; 36:115-127.
- 39 Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. *J Clin Oncol* 2005; 23:6364-6369.
- 40 Salaverria I, Perez-Galan P, Colomer D, Campo E. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. *Haematologica* 2006; 91:11-16.
- 41 Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. *Nat Rev Cancer* 2007; 7:750-762.
- 42 Thorselius M, Walsh S, Eriksson I, Thunberg U, Johnson A, Backlin C et al. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. *Eur J Haematol* 2002; 68:217-224.
- 43 Bertoni F, Conconi A, Cogliatti SB, Schmitz SF, Ghielmini M, Cerny T et al. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. *Br J Haematol* 2004; 124:289-298.
- 44 Cogliatti SB, Bertoni F, Zimmermann DR, Henz S, Diss TC, Ghielmini M et al. IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. *J Pathol* 2005; 206:320-327.
- 45 Bertoni F, Ponzoni M. The cellular origin of mantle cell lymphoma. *Int J Biochem Cell Biol* 2007.
- 46 Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. *Blood* 1999; 93:4365-4374.

- 47 Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. *Blood* 1994; 84:2726-2732.
- 48 Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. *Cancer Cell* 2003; 3:185-197.
- 49 Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. *Blood* 2000; 95:2253-2261.
- 50 Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. *EMBO J* 1994; 13:3487-3495.
- 51 Monni O, Oinonen R, Elonen E, Franssila K, Teerenhovi L, Joensuu H et al. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. *Genes Chromosomes Cancer* 1998; 21:298-307.
- 52 Stilgenbauer S, Winkler D, Ott G, Schaffner C, Leupolt E, Bentz M et al. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. *Blood* 1999; 94:3262-3264.
- 53 Camacho E, Hernandez L, Hernandez S, Tort F, Bellosillo B, Bea S et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. *Blood* 2002; 99:238-244.
- 54 Tort F, Hernandez S, Bea S, Martinez A, Esteller M, Herman JG et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. *Blood* 2002; 100:4602-4608.
- 55 Tort F, Hernandez S, Bea S, Camacho E, Fernandez V, Esteller M et al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. *Leukemia* 2005; 19:112-117.
- 56 Salaverria I, Zettl A, Bea S, Moreno V, Valls J, Hartmann E et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. *J Clin Oncol* 2007; 25:1216-1222.
- 57 Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. *Blood* 1997; 89:2067-2078.
- 58 de Vos S, Krug U, Hofmann WK, Pinkus GS, Swerdlow SH, Wachsman W et al. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. *Diagn Mol Pathol* 2003; 12:35-43.

- 59 Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. *Leukemia* 2007; 21:18-29.
- 60 Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. *Hematology (Am Soc Hematol Educ Program)* 2004;203-220.
- 61 Dunphy CH. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. *Arch Pathol Lab Med* 2006; 130:483-520.
- 62 Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *N Engl J Med* 2004; 351:2159-2169.
- 63 De Paepe P, Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. *Leukemia* 2007; 21:37-43.
- 64 Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. *Leuk Lymphoma* 2003; 44 Suppl 3:S41-S47.
- 65 Dybkaer K, Iqbal J, Zhou G, Chan WC. Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma. *Clin Lymphoma* 2004; 5:19-28.
- 66 Bai M, Skyras A, Agnantis NJ, Kamina S, Papoudou-Bai A, Kitsoulis P et al. B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. *Anticancer Res* 2005; 25:347-362.
- 67 Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000; 100:57-70.
- 68 Golias CH, Charalabopoulos A, Charalabopoulos K. Cell proliferation and cell cycle control: a mini review. *Int J Clin Pract* 2004; 58:1134-1141.
- 69 Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. *Nat Rev Mol Cell Biol* 2007; 8:149-160.
- 70 Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. *Trends Biochem Sci* 2005; 30:630-641.
- 71 Kato JY, Matsuoka M, Strom DK, Sherr CJ. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. *Mol Cell Biol* 1994; 14:2713-2721.
- 72 Karlsson-Rosenthal C, Millar JB. Cdc25: mechanisms of checkpoint inhibition and recovery. *Trends Cell Biol* 2006; 16:285-292.
- 73 Obaya AJ, Sedivy JM. Regulation of cyclin-Cdk activity in mammalian cells. *Cell Mol Life Sci* 2002; 59:126-142.
- 74 Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. *Br J Cancer* 2001; 85:1813-1823.
- 75 Fisher DE. The p53 tumor suppressor: critical regulator of life & death in cancer. *Apoptosis* 2001; 6:7-15.

- 76 Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. *Mol Cell* 2006; 21:307-315.
- 77 Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. *Cell* 2004; 119:591-602.
- 78 Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. *Blood* 2003; 101:1220-1235.
- 79 Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. *Cell Prolif* 2003; 36:165-175.
- 80 Liu J, Levens D. Making myc. *Curr Top Microbiol Immunol* 2006; 302:1-32.
- 81 Katzenberger T, Petzoldt C, Holler S, Mader U, Kalla J, Adam P et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. *Blood* 2006; 107:3407.
- 82 Pasqualucci L, Bereschenko O, Niu H, Klein U, Basso K, Guglielmino R et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. *Leuk Lymphoma* 2003; 44 Suppl 3:S5-12.
- 83 Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. *Nature* 1985; 315:340-343.
- 84 Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. *Nature* 1991; 350:512-515.
- 85 Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. *Blood* 1996; 87:4302-4310.
- 86 Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. *Blood* 1996; 87:3351-3359.
- 87 Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VV, Schluger A et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). *Blood* 1995; 86:2892-2899.
- 88 Hernandez L, Bea S, Pinyol M, Ott G, Katzenberger T, Rosenwald A et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. *Cancer Res* 2005; 65:2199-2206.
- 89 Moller MB, Nielsen O, Pedersen NT. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. *Mod Pathol* 1999; 12:1010-1016.
- 90 Pagnano KB, Vassallo J, Lorand-Metze I, Costa FF, Saad ST. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. *Am J Hematol* 2001; 67:84-92.

- 91 Solenthaler M, Matutes E, Brito-Babapulle V, Morilla R, Catovsky D. p53 and mdm2 in mantle cell lymphoma in leukemic phase. *Haematologica* 2002; 87:1141-1150.
- 92 Pinyol M, Hernandez L, Cazorla M, Balbin M, Jares P, Fernandez PL et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. *Blood* 1997; 89:272-280.
- 93 Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. *Blood* 1998; 91:2977-2984.
- 94 Gronbaek K, Nedergaard T, Andersen MK, Thor SP, Guldborg P, Moller P et al. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. *Leukemia* 1998; 12:1266-1271.
- 95 Pinyol M, Hernandez L, Martinez A, Cobo F, Hernandez S, Bea S et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. *Am J Pathol* 2000; 156:1987-1996.
- 96 Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. *Cancer Res* 2001; 61:2409-2412.
- 97 Pinyol M, Bea S, Pla L, Ribrag V, Bosq J, Rosenwald A et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. *Blood* 2007; 109:5422-5429.
- 98 Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. *Leukemia* 2001; 15:1785-1791.
- 99 Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. *Cancer* 1998; 82:567-575.
- 100 Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. *Br J Haematol* 2005; 131:29-38.
- 101 Schrader C, Janssen D, Klapper W, Siebmann JU, Meusers P, Brittinger G et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. *Br J Cancer* 2005; 93:939-945.
- 102 Schrader C, Janssen D, Meusers P, Brittinger G, Siebmann JU, Parwaresch R et al. Repp86: a new prognostic marker in mantle cell lymphoma. *Eur J Haematol* 2005; 75:498-504.
- 103 de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma:

- validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. *J Clin Oncol* 2007; 25:805-812.
- 104 Fesik SW. Insights into programmed cell death through structural biology. *Cell* 2000; 103:273-282.
- 105 Danial NN, Korsmeyer SJ. Cell death: critical control points. *Cell* 2004; 116:205-219.
- 106 Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. *Nat Rev Cancer* 2002; 2:277-288.
- 107 Rossi D, Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. *Haematologica* 2003; 88:212-218.
- 108 Reed JC. Molecular biology of chronic lymphocytic leukemia. *Semin Oncol* 1998; 25:11-18.
- 109 Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. *Semin Oncol* 2002; 29:10-24.
- 110 Danilov AV, Danilova OV, Klein AK, Huber BT. Molecular pathogenesis of chronic lymphocytic leukemia. *Curr Mol Med* 2006; 6:665-675.
- 111 de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. *J Clin Oncol* 2005; 23:6358-6363.
- 112 Rummel MJ, de Vos S, Hoelzer D, Koeffler HP, Hofmann WK. Altered apoptosis pathways in mantle cell lymphoma. *Leuk Lymphoma* 2004; 45:49-54.
- 113 Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. *Cancer Res* 2003; 63:8226-8232.
- 114 Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. *Blood* 2006; 108:1668-1676.
- 115 Wu G, Keating A. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. *Cancer* 2006; 106:247-257.
- 116 Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. *Cell Res* 2004; 14:359-372.
- 117 Degli-Esposti M. To die or not to die--the quest of the TRAIL receptors. *J Leukoc Biol* 1999; 65:535-542.
- 118 MacFarlane M. TRAIL-induced signalling and apoptosis. *Toxicol Lett* 2003; 139:89-97.
- 119 Greil R, Anether G, Johrer K, Tinhofer I. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools. *J Leukoc Biol* 2003; 74:311-330.

- 120 Wu GS, Burns TF, McDonald ER, III, Jiang W, Meng R, Krantz ID et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. *Nat Genet* 1997; 17:141-143.
- 121 Martinez-Climent JA, Vizcarra E, Sanchez D, Blesa D, Marugan I, Benet I et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. *Blood* 2001; 98:3479-3482.
- 122 Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martin-Subero JI, Nielande I et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. *Blood* 2005; 105:4445-4454.
- 123 Rubio-Moscardo F, Blesa D, Mestre C, Siebert R, Balasas T, Benito A et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. *Blood* 2005; 106:3214-3222.
- 124 Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. *Leukemia* 2005; 19:2195-2202.
- 125 Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, Colomer D. Selective inhibition of I κ B kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. *J Immunol* 2007; 178:1923-1930.
- 126 Arai T, Akiyama Y, Okabe S, Saito K, Iwai T, Yuasa Y. Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas. *Cancer Lett* 1998; 133:197-204.
- 127 Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. *Cancer Res* 1999; 59:5683-5686.
- 128 Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. *Oncogene* 2001; 20:399-403.
- 129 Ozoren N, El Deiry WS. Cell surface Death Receptor signaling in normal and cancer cells. *Semin Cancer Biol* 2003; 13:135-147.
- 130 Pai SI, Wu GS, Ozoren N, Wu L, Jen J, Sidransky D et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. *Cancer Res* 1998; 58:3513-3518.
- 131 Seitz S, Wassmuth P, Fischer J, Nothnagel A, Jandrig B, Schlag PM et al. Mutation analysis and mRNA expression of trail-receptors in human breast cancer. *Int J Cancer* 2002; 102:117-128.
- 132 Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. *Clin Cancer Res* 2001; 7:1688-1697.
- 133 Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X. Death receptor 4 and bladder cancer risk. *Cancer Res* 2003; 63:1157-1159.

- 134 Kim K, Fisher MJ, Xu SQ, El Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. *Clin Cancer Res* 2000; 6:335-346.
- 135 Kuraoka K, Matsumura S, Sanada Y, Nakachi K, Imai K, Eguchi H et al. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. *Oncol Rep* 2005; 14:465-470.
- 136 Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, Grone HJ et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. *Int J Cancer* 2006; 118:1831-1835.
- 137 MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. *Cell Death Differ* 2005; 12:773-782.
- 138 MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. *Cancer Res* 2005; 65:11265-11270.
- 139 Matolcsy A. High-grade transformation of low-grade non-Hodgkin's lymphomas: mechanisms of tumor progression. *Leuk Lymphoma* 1999; 34:251-259.
- 140 Muller-Hermelink HK, Zettl A, Pfeifer W, Ott G. Pathology of lymphoma progression. *Histopathology* 2001; 38:285-306.
- 141 Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. *Oncologist* 2006; 11:21-30.
- 142 Seiler T, Dohner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. *Semin Oncol* 2006; 33:186-194.
- 143 Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. *Blood* 1975; 46:219-234.
- 144 Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vaugier G et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. *Cancer* 1977; 40:855-864.
- 145 Pangalis GA, Vassilakopoulos TP, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Angelopoulou MK. B-chronic lymphocytic leukemia: practical aspects. *Hematol Oncol* 2002; 20:103-146.
- 146 Montserrat E. New Prognostic Markers in CLL. *Hematology Am Soc Hematol Educ Program* 2006;279-284.
- 147 Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. *Semin Oncol* 1998; 25:42-59.
- 148 Athanasiadou A, Stamatopoulos K, Tsompanakou A, Gaitatzi M, Kalogiannidis P, Anagnostopoulos A et al. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. *Cancer Genet Cytogenet* 2006; 168:109-119.

- 149 Juliusson G, Friberg K, Gahrton G. Consistency of chromosomal aberrations in chronic B-lymphocytic leukemia. A longitudinal cytogenetic study of 41 patients. *Cancer* 1988; 62:500-506.
- 150 Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. *J Exp Med* 2001; 194:1639-1647.
- 151 Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. *Leukemia* 2002; 16:993-1007.
- 152 Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. *Br J Haematol* 1986; 62:567-575.
- 153 Molica S, Levato D, Cascavilla N, Levato L, Musto P. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. *Eur J Haematol* 1999; 62:117-122.
- 154 Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. *Blood* 1999; 93:1732-1737.
- 155 Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). *Leukemia* 2002; 16:1045-1052.
- 156 Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. *J Exp Med* 2001; 194:1625-1638.
- 157 Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. *Lancet* 2004; 363:105-111.
- 158 Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *N Engl J Med* 2005; 353:1793-1801.
- 159 Deglesne PA, Chevallier N, Letestu R, Baran-Marszak F, Beitar T, Salanoubat C et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of zap70 expression. *Cancer Res* 2006; 66:7158-7166.
- 160 Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. *J Clin Oncol* 2004; 22:3937-3949.

- 161 Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. *Mol Cancer Res* 2003; 1:346-361.
- 162 Vasconcelos Y, De Vos J, Vallat L, Reme T, Lalanne AI, Wanherdrick K et al. Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. *Leukemia* 2005; 19:2002-2005.
- 163 Falt S, Merup M, Gahrton G, Lambert B, Wennborg A. Identification of progression markers in B-CLL by gene expression profiling. *Exp Hematol* 2005; 33:883-893.
- 164 Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. *Genes Chromosomes Cancer* 1994; 10:231-243.
- 165 Pinkel D, Albertson DG. Comparative genomic hybridization. *Annu Rev Genomics Hum Genet* 2005; 6:331-354.
- 166 Matsuzaki H, Dong S, Loi H, Di X, Liu G, Hubbell E et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. *Nat Methods* 2004; 1:109-111.
- 167 Matsuzaki H, Loi H, Dong S, Tsai YY, Fang J, Law J et al. Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. *Genome Res* 2004; 14:414-425.
- 168 Hayashi K. PCR-SSCP: a method for detection of mutations. *Genet Anal Tech Appl* 1992; 9:73-79.
- 169 Lessa EP, Applebaum G. Screening techniques for detecting allelic variation in DNA sequences. *Mol Ecol* 1993; 2:119-129.
- 170 Ganguly A. An update on conformation sensitive gel electrophoresis. *Hum Mutat* 2002; 19:334-342.
- 171 Guzowski D, Chandrasekaran A, Gawel C, Palma J, Koenig J, Wang XP et al. Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. *J Biomol Tech* 2005; 16:154-166.
- 172 Janne PA, Borrás AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. *Clin Cancer Res* 2006; 12:751-758.
- 173 Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: A review. *Hum Mutat* 2001; 17:439-474.
- 174 Premstaller A, Oefner PJ. Denaturing high-performance liquid chromatography. *Methods Mol Biol* 2003; 212:15-35.
- 175 Meetei AR, Rao MR. Generation of multiple site-specific mutations by polymerase chain reaction. *Methods Mol Biol* 2002; 182:95-102.

- 176 Raval P. Qualitative and quantitative determination of mRNA. *J Pharmacol Toxicol Methods* 1994; 32:125-127.
- 177 Greil K, Gattlinger C, Fasching B, Cleveland J, Thaler J, Radaskiewicz T et al. *abl* oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status. *Int J Cancer* 1988; 42:529-538.
- 178 Hamada M, Yakushijin Y, Ohtsuka M, Kakimoto M, Yasukawa M, Fujita S. Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma. *Br J Haematol* 2003; 121:439-447.
- 179 Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. *Methods* 2001; 25:386-401.
- 180 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-(\Delta\Delta C(T))}$ Method. *Methods* 2001; 25:402-408.
- 181 Lossos IS, Czerwinski DK, Wechser MA, Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. *Leukemia* 2003; 17:789-795.
- 182 Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5'→3' exonuclease activity of *Thermus aquaticus* DNA polymerase. *Proc Natl Acad Sci U S A* 1991; 88:7276-7280.
- 183 Cardullo RA, Parpura V. Fluorescence resonance energy transfer microscopy: theory and instrumentation. *Methods Cell Biol* 2003; 72:415-430.
- 184 Goff LK, Neat MJ, Crawley CR, Jones L, Jones E, Lister TA et al. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the *REL* gene in follicular lymphoma. *Br J Haematol* 2000; 111:618-625.
- 185 Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. *Am J Pathol* 2004; 164:35-42.
- 186 Copland JA, Davies PJ, Shipley GL, Wood CG, Luxon BA, Urban RJ. The use of DNA microarrays to assess clinical samples: the transition from bedside to bench to bedside. *Recent Prog Horm Res* 2003; 58:25-53.
- 187 Southern EM. DNA microarrays. History and overview. *Methods Mol Biol* 2001; 170:1-15.
- 188 Alizadeh AA, Ross DT, Perou CM, van de RM. Towards a novel classification of human malignancies based on gene expression patterns. *J Pathol* 2001; 195:41-52.
- 189 Young RA. Biomedical discovery with DNA arrays. *Cell* 2000; 102:9-15.

- 190 Bertucci F, Houlgatte R, Nguyen C, Viens P, Jordan BR, Birnbaum D. Gene expression profiling of cancer by use of DNA arrays: how far from the clinic? *Lancet Oncol* 2001; 2:674-682.
- 191 Cheung VG, Morley M, Aguilar F, Massimi A, Kucherlapati R, Childs G. Making and reading microarrays. *Nat Genet* 1999; 21:15-19.
- 192 Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. *Proc Natl Acad Sci U S A* 1994; 91:5022-5026.
- 193 Staal FJ, Cario G, Cazzaniga G, Haferlach T, Heuser M, Hofmann WK et al. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. *Leukemia* 2006; 20:1385-1392.
- 194 Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. *Nat Rev Genet* 2006; 7:55-65.
- 195 Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S. *Bioinformatics and computational biology solutions using R and Bioconductor*. Springer, 2005.
- 196 Harr B, Schlotterer C. Comparison of algorithms for the analysis of Affymetrix microarray data as evaluated by co-expression of genes in known operons. *Nucleic Acids Res* 2006; 34:e8.
- 197 Shedden K, Chen W, Kuick R, Ghosh D, Macdonald J, Cho KR et al. Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. *BMC Bioinformatics* 2005; 6:26.
- 198 Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. *Nucleic Acids Res* 2003; 31:e15.
- 199 Ochs MF, Godwin AK. Microarrays in cancer: research and applications. *Biotechniques* 2003; Suppl:4-15.
- 200 Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A* 1998; 95:14863-14868.
- 201 Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS et al. Knowledge-based analysis of microarray gene expression data by using support vector machines. *Proc Natl Acad Sci U S A* 2000; 97:262-267.
- 202 Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. *Nat Med* 2001; 7:673-679.
- 203 Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. *Am J Pathol* 2001; 158:419-429.
- 204 Sunnucks P, Wilson AC, Beheregaray LB, Zenger K, French J, Taylor AC. SSCP is not so difficult: the application and utility of single-stranded conformation polymorphism in evolutionary biology and molecular ecology. *Mol Ecol* 2000; 9:1699-1710.

- 205 Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. *Eur J Haematol* 2002; 69:11-20.
- 206 Witzig TE. Current treatment approaches for mantle-cell lymphoma. *J Clin Oncol* 2005; 23:6409-6414.
- 207 Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K et al. Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma. *Blood* 2007.
- 208 Nagy B, Lundan T, Larramendy ML, Aalto Y, Zhu Y, Niini T et al. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. *Br J Haematol* 2003; 120:434-441.
- 209 Arnaoutov A, Dasso M. The Ran GTPase regulates kinetochore function. *Dev Cell* 2003; 5:99-111.
- 210 Dasso M. The Ran GTPase: theme and variations. *Curr Biol* 2002; 12:R502-R508.
- 211 Janz S. Myc translocations in B cell and plasma cell neoplasms. *DNA Repair (Amst)* 2006; 5:1213-1224.
- 212 Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F et al. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. *Leukemia* 1999; 13:2087-2093.
- 213 Korz C, Pscherer A, Benner A, Mertens D, Schaffner C, Leupolt E et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. *Blood* 2002; 99:4554-4561.
- 214 Burgers PM. Eukaryotic DNA polymerases in DNA replication and DNA repair. *Chromosoma* 1998; 107:218-227.
- 215 Hubscher U, Nasheuer HP, Syvaaja JE. Eukaryotic DNA polymerases, a growing family. *Trends Biochem Sci* 2000; 25:143-147.
- 216 Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. *Pflugers Arch* 2004; 447:735-743.
- 217 Marce S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. *Haematologica* 2006; 91:895-902.
- 218 Molina-Arcas M, Marce S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B et al. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. *Leukemia* 2005; 19:64-68.

- 219 Mizuno T, Nagamura H, Iwamoto KS, Ito T, Fukuhara T, Tokunaga M et al. RNA from decades-old archival tissue blocks for retrospective studies. *Diagn Mol Pathol* 1998; 7:202-208.
- 220 Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. *Nucleic Acids Res* 1999; 27:4436-4443.
- 221 Mies C. A simple, rapid method for isolating RNA from paraffin-embedded tissues for reverse transcription-polymerase chain reaction (RT-PCR). *J Histochem Cytochem* 1994; 42:811-813.
- 222 Rupp GM, Locker J. Purification and analysis of RNA from paraffin-embedded tissues. *Biotechniques* 1988; 6:56-60.
- 223 Stanta G, Bonin S. RNA quantitative analysis from fixed and paraffin-embedded tissues: membrane hybridization and capillary electrophoresis. *Biotechniques* 1998; 24:271-276.
- 224 Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. *Am J Pathol* 2004; 164:35-42.
- 225 Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. *Nucleic Acids Res* 1998; 26:3453-3459.
- 226 Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A et al. MDM2 protein expression is a negative prognostic marker in breast carcinoma. *Mod Pathol* 2006; 19:69-74.
- 227 Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. *Cancer Res* 2006; 66:5104-5110.
- 228 Onel K, Cordon-Cardo C. MDM2 and prognosis. *Mol Cancer Res* 2004; 2:1-8.
- 229 MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. *J Biol Chem* 1997; 272:25417-25420.
- 230 Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. *Curr Biol* 1997; 7:1003-1006.
- 231 Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. *Cancer Res* 2001; 61:4942-4946.
- 232 McDonald ER, III, Chui PC, Martelli PF, Dicker DT, El Deiry WS. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. *J Biol Chem* 2001; 276:14939-14945.

- 233 Park WS, Lee JH, Shin MS, Park JY, Kim HS, Kim YS et al. Inactivating mutations of KILLER/DR5 gene in gastric cancers. *Gastroenterology* 2001; 121:1219-1225.
- 234 Wu WG, Soria JC, Wang L, Kemp BL, Mao L. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. *Anticancer Res* 2000; 20:4525-4529.
- 235 Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. *J Clin Invest* 1999; 104:155-162.
- 236 Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. *Nat Med* 1999; 5:157-163.
- 237 MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. *Oncogene* 2002; 21:6809-6818.
- 238 Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. *Br J Haematol* 1997; 99:618-624.
- 239 Krober A, Bloehdorn J, Hafner S, Buhler A, Seiler T, Kienle D et al. Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia. *J Clin Oncol* 2006; 24:969-976.
- 240 Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. *Blood* 1997; 89:4153-4160.
- 241 Callet-Bauchu E, Salles G, Gazzo S, Poncet C, Morel D, Pages J et al. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. *Leukemia* 1999; 13:460-468.
- 242 Michaux L, Wlodarska I, Rack K, Stul M, Criel A, Maerevoet M et al. Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL. *Leukemia* 2005; 19:77-82.
- 243 Peterson LC, Lindquist LL, Church S, Kay NE. Frequent clonal abnormalities of chromosome band 13q14 in B-cell chronic lymphocytic leukemia: multiple clones, subclones, and nonclonal alterations in 82 midwestern patients. *Genes Chromosomes Cancer* 1992; 4:273-280.
- 244 Geisler CH, Philip P, Christensen BE, Hou-Jensen K, Pedersen NT, Jensen OM et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. *Leuk Res* 1997; 21:1011-1023.
- 245 Garcia-Marco JA, Price CM, Catovsky D. Interphase cytogenetics in chronic lymphocytic leukemia. *Cancer Genet Cytogenet* 1997; 94:52-58.

- 246 Hjalmar V, Hast R, Kimby E. Sequential fluorescence in situ hybridization analyses for trisomy 12 in chronic leukemic B-cell disorders. *Haematologica* 2001; 86:174-180.
- 247 Brynes RK, McCourty A, Sun NC, Koo CH. Trisomy 12 in Richter's transformation of chronic lymphocytic leukemia. *Am J Clin Pathol* 1995; 104:199-203.
- 248 Finn WG, Kay NE, Kroft SH, Church S, Peterson LC. Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients. *Am J Hematol* 1998; 59:223-229.
- 249 el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. *Blood* 1993; 82:3452-3459.
- 250 Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MA, De Lord C et al. Deletions and rearrangement of CDKN2 in lymphoid malignancy. *Blood* 1995; 85:893-901.
- 251 Matolcsy A, Inghirami G, Knowles DM. Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma). *Blood* 1994; 83:1363-1372.
- 252 Durig J, Nuckel H, Huttmann A, Kruse E, Holter T, Halfmeyer K et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. *Blood* 2003; 101:2748-2755.
- 253 Haran M, Chebatco S, Flaishon L, Lantner F, Harpaz N, Valinsky L et al. Grb7 expression and cellular migration in chronic lymphocytic leukemia: a comparative study of early and advanced stage disease. *Leukemia* 2004; 18:1948-1950.
- 254 Richardson SJ, Matthews C, Catherwood MA, Alexander HD, Carey BS, Farrugia J et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B cell chronic lymphocytic leukaemia (B-CLL). *Blood* 2006; 107:3584-3592.